SavedAdd your journal

Journals / Fırat Tıp Dergisi / 2011 / Cilt: 16 - Sayı: 4

Inoperabl gastrointestinal tümörde ımatinib mesilat tedavisi sonrası patolojik tam yanıt: olgu sunumu

Pathological complete response after imatinib mesylate therapy in ınoperabl gastrointestinal stromal tumor: A case report

Baha ZENGEL
AHMET ALACACIOĞLU
Ayşe YAĞCI
Hakan POSTACI
Özgür KAVAK
Galip Ali DENECLI
Erhan GÖKMEN
Pages
206–208
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

We present a 46 year old man patient with unresectable gastrointestinal stromal tumor that has histopatologically proven complete response to imatinib mesylate therapy.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Gastrointestinal stromal tumors are characterized by the expression of CD34 and c-kit (CD117) and represent the most common mesenchymal malig- nancy of the gastrointestinal tract.
📊
Key Findings & Data:Clinical studies for metastatic and inoperabl GISTs have demonstrated partial response rate ranging from 40% to 69% in patients treated with imatinib mesylate.
💡
Conclusion & Impact:We present a 46 year old man patient with unresectable gastrointestinal stromal tumor that has histopatologically proven complete response to imatinib mesylate therapy.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Gastrointestinal stromal tumors are characterized by the expression of CD34 and c-kit (CD117) and represent the most common mesenchymal malig- nancy of the gastrointestinal tract. Imatinib mesylate is small molecule tyrosine kinase inhibitor that suppresses transmembrane receptor c-kit pro- ducts. Clinical studies for metastatic and inoperabl GISTs have demonstrated partial response rate ranging from 40% to 69% in patients treated with imatinib mesylate. But complete response is rare. We present a 46 year old man patient with unresectable gastrointestinal stromal tumor that has histopatologically proven complete response to imatinib mesylate therapy.

Özet

Gastrointestinal stromal tümörler CD34 and c-kit (CD117) ekspresyonu ile karekterize olan, gastrointestinal sistemin en sık görülen mezenkimal maligniteleridir. İmatinib mesiat, transmembran reseptör c-kit ürünlerini baskılayan küçük molekül tirozin kinaz inhibitörüdür. Metastatik ve inope- rabl gastarointestinal stromal tümörlerde yapılan klinik çalışmalarda imatinib mesilat tedavisi ile parsiyel yanıt oranları 40% ile 69% arasındadır. Fakat tam yanıt nadirdir. Bu yazımızda 46 yaşında anrezektabl gastrointestinal stromal tümorlü erkek hastada, imatinib mesilat tedavisi ile sağlanan patolojik tam yanıt değerlendirilmiştir.

🔖

Cite This Article

ZENGEL, B., ALACACIOĞLU, A., YAĞCI, A., POSTACI, H., KAVAK, Ö., DENECLI, G. A., GÖKMEN, E. (2011). Inoperabl gastrointestinal tümörde ımatinib mesilat tedavisi sonrası patolojik tam yanıt: olgu sunumu. Fırat Tıp Dergisi, Cilt: 16 - Sayı: 4, 206–208. https://ajindex.com/articles/223642

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (1)

  1. Demetri GD. Gastrointestinal stromal tumor. In: Cancer: Prin- ciples and practice of oncology, 8th ed, DeVita VT, Hellman S, Rosenberg SA (Eds), p 1257,Lippincott-Williams &Wilkins, Philadelphia, 2008. 2.Mazur MT, Clark HB. Gastric stromal tumors. Reappraisal of histogenesis. Am J Surg Pathol 1983; 7: 507-519. 3.Kindblom LG, Remotti HE, Aldenborg F, Meis-Kindblom JM. Gastrointestinal pacemaker cell tumor (GIPACT): gastrointes- tinal stromal tumors show phenotypic characteristic of the in- tersititial cell of Cajal. Am J Pathol 1998; 152: 1259-1269. 4.Chiang KC, Chen TW, Yeh CN, Liu FY, Lee HL, Jan YY. Advanced gastrointestinal stromal tumor patients with comple- te response after treatment with imatinib mesylate. World J Gastroenterol 2006; 12: 2060-2064. 5.Melichar B, Voboril Z, Nozicka J, et al. Pathological complete response in advanced gastrointestinal stromal tumor after ima- tinib therapy. Internal Medicine 2005; 44: 1163-1168. 6.Joensuu H, Roberts PJ, Sarlomo-Rikala M, et al. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Eng J Med 2001; 344: 1052- 1056. 7.Andtbacka RH, Ng CS, Scaife CL, et al. Surgical resection of gastrointestinal stromal tumors after treatment with imatinib. Ann Surg Oncol 2007; 14: 14-24. 8.Gronchi A, Fiore M, Miselli F, et al. Surgery of residual disea- se following molecular-targeted therapy with imatinib mesyla- te in advanced/metastatic GIST. Ann Surg 2007; 245: 341- 346. 9.Nishida T, Shirao K, Sawaki A, et al. Efficacy and safety profile of imatinib mesylate (ST1571) in Japanese patients with advanced gastrointestinal stromal tumors: a phase II study (STI571B1202). Int J Clin Oncol 2008; 13: 244-251. 10.Goh BK, Chow PK, Chuah KL, Yap WM, Wong WK. Patho- logic, radiologic and PET scan response of gastrointestinal stromal tumors after neoadjuvant treatment with imatinib mesylate. Eur J Surg Oncol 2006; 32: 961-963. 11.Salazar M, Barata A, André S, et al. First reportof a complete pathological response of a pelvic GIST treatedwith imatinib as neoadjuvant therapy.Gut. 2006; 55: 585-586. 12.Suzuki S, Sasajima K, Miyamoto M, et al. Pathologic complete response confirmed by surgical resection for liver metastases of gastrointestinal stromal tumor after treatment with imatinib mesylate. World J Gastroenterol 2008; 14: 3763-3767.